Summit Therapeutics Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Summit Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q3 2024.
  • Summit Therapeutics Inc. Debt-to-equity for the quarter ending September 30, 2024 was 62.2 %, a 66.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 62.2 -125 -66.7% Sep 30, 2024
Q2 2024 126 -29.9 -19.2% Jun 30, 2024
Q1 2024 145 -18 -11% Mar 31, 2024
Q4 2023 112 -62.3 -35.6% Dec 31, 2023
Q3 2023 187 +142 +318% Sep 30, 2023
Q2 2023 156 +105 +207% Jun 30, 2023
Q1 2023 163 +127 +348% Mar 31, 2023
Q4 2022 175 +132 +306% Dec 31, 2022
Q3 2022 44.7 +3.19 +7.68% Sep 30, 2022
Q2 2022 50.8 +2.54 +5.27% Jun 30, 2022
Q1 2022 36.4 -22.2 -37.9% Mar 31, 2022
Q4 2021 43 Dec 31, 2021
Q3 2021 41.6 Sep 30, 2021
Q2 2021 48.2 Jun 30, 2021
Q1 2021 58.7 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.